Literature DB >> 7755506

Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: implications on HIV vaccine development.

R Wagner1, L Deml, R Schirmbeck, J Reimann, H Wolf.   

Abstract

New insights into HIV-pathogenesis suggest that the cell mediated immune response might play a crucial role in controlling HIV infection by suppressing HIV-replication in CD4-positive cells by a lymphokine-like soluble factor and by killing HIV-infected cells via classical CTL mediated lysis. This type of a cellular immune response rather than an antibody response seems to be most promising to protect if not from infection, so at least from disease. Therefore rationally designed candidate vaccines should be capable of inducing a cell mediated immunity in addition to a humoral immune response. In order to avoid adverse side effects upon immunization, carefully selected antigens and epitopes should be presented in a favourable manner to the immune system. In previous experiments, we could demonstrate that the gag-polyprotein precursor, known to include a series of T-helper and CTL epitopes, assembles to highly immunogenic, complete noninfectious HIV-1 virus-like particles (VLP). Based on these VLP we developed a novel antigen presentation system, which allows the presentation of selected epitopes derived from HIV reading frames other than gag to the immune system. Alternatively complete derivatives of the HIV-1 external glycoprotein can be presented by the VLP. Immunological analysis of different VLP preparations in a BALB/c mouse model revealed the induction of a strong CTL response. The significance of these observations for future vaccine strategies is discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7755506

Source DB:  PubMed          Journal:  Behring Inst Mitt        ISSN: 0301-0457


  4 in total

1.  Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.

Authors:  Luis M Branco; Jessica N Grove; Frederick J Geske; Matt L Boisen; Ivana J Muncy; Susan A Magliato; Lee A Henderson; Randal J Schoepp; Kathleen A Cashman; Lisa E Hensley; Robert F Garry
Journal:  Virol J       Date:  2010-10-20       Impact factor: 4.099

2.  Immunogenicity in Rabbits of Virus-Like Particles from a Contemporary Rabbit Haemorrhagic Disease Virus Type 2 (GI.2/RHDV2/b) Isolated in The Netherlands.

Authors:  Qiuhong Miao; Ruibing Qi; Luut Veldkamp; Jooske Ijzer; Marja L Kik; Jie Zhu; Aoxing Tang; Dandan Dong; Yonghong Shi; Monique M van Oers; Guangqing Liu; Gorben P Pijlman
Journal:  Viruses       Date:  2019-06-14       Impact factor: 5.048

Review 3.  Virus like particle-based vaccines against emerging infectious disease viruses.

Authors:  Jinliang Liu; Shiyu Dai; Manli Wang; Zhihong Hu; Hualin Wang; Fei Deng
Journal:  Virol Sin       Date:  2016-07-11       Impact factor: 4.327

Review 4.  Virus-like particles-universal molecular toolboxes.

Authors:  Christine Ludwig; Ralf Wagner
Journal:  Curr Opin Biotechnol       Date:  2007-12       Impact factor: 9.740

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.